Pharmacyte Biotech Inc (PMCB) 0.0431 $PMCB
Dr. Mark L. Rabe Presents PharmaCyte Biotech's Ongoing Research at Cannabis Cancer Forum
GlobeNewswire - Tue Aug 02, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that on Saturday, July 30, 2016, PharmaCyte's Medical and Scientific Advisory Board member Mark L. Rabe, MD, delivered a presentation entitled "Medical Cannabis for Cancer" as part of a "Cannabis for Cancer Forum" in San Diego.
PharmaCyte Biotech Releases Shareholder Call Playback Information
GlobeNewswire - Fri Jul 29, 8:01AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that an audio recording of the company's shareholder call, which was held on July 28, 2016, by Chief Executive Officer Kenneth L. Waggoner is now available for playback.
Extraction Technology Becoming Paramount in Cannabis Industry as Consumers Gravitate Towards Concentrates and Higher Quality of Substance
CNW Group - Tue Jul 19, 7:30AM CDT
Top marijuana companies are aiming to improve cannabis extraction methods as the market value shifts towards concentrates and higher quality of substances for both medical and recreational uses. Marijuana concentrates are the fastest growing segment of Colorado's legal marijuana market. Marijuana, Hemp & Cannabis Operations are being guided in the markets today by Puration, Inc. (OTC: PURA), PharmaCyte Biotech, Inc. (OTC: PMCB), GrowLife, Inc. (OTC: PHOT), Hemp, Inc. (OTC: HEMP) & Medical Marijuana, Inc. (OTC: MJNA).
PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu Jul 14, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes.
Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 95.62 (+0.22), MSFT: 57.96 (+0.57)
PharmaCyte Biotech to Hold Shareholder Call
GlobeNewswire - Mon Jul 11, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chief Executive Officer, Kenneth L. Waggoner, will conduct a shareholder conference call at 4:30 p.m. EDT on Thursday, July 28, 2016.
PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media.
PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.
PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research."
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.17 (-0.07)
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.
PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.
PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016.
PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology.
PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
JNJ: 124.24 (+0.38)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.
Dr. Mark L. Rabe Presents PharmaCyte Biotech's Ongoing Research at Cannabis Cancer Forum
GlobeNewswire - Tue Aug 02, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that on Saturday, July 30, 2016, PharmaCyte's Medical and Scientific Advisory Board member Mark L. Rabe, MD, delivered a presentation entitled "Medical Cannabis for Cancer" as part of a "Cannabis for Cancer Forum" in San Diego. PharmaCyte Biotech Releases Shareholder Call Playback Information
GlobeNewswire - Fri Jul 29, 8:01AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that an audio recording of the company's shareholder call, which was held on July 28, 2016, by Chief Executive Officer Kenneth L. Waggoner is now available for playback. Extraction Technology Becoming Paramount in Cannabis Industry as Consumers Gravitate Towards Concentrates and Higher Quality of Substance
CNW Group - Tue Jul 19, 7:30AM CDT
Top marijuana companies are aiming to improve cannabis extraction methods as the market value shifts towards concentrates and higher quality of substances for both medical and recreational uses. Marijuana concentrates are the fastest growing segment of Colorado's legal marijuana market. Marijuana, Hemp & Cannabis Operations are being guided in the markets today by Puration, Inc. (OTC: PURA), PharmaCyte Biotech, Inc. (OTC: PMCB), GrowLife, Inc. (OTC: PHOT), Hemp, Inc. (OTC: HEMP) & Medical Marijuana, Inc. (OTC: MJNA).
PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu Jul 14, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes. Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 95.62 (+0.22), MSFT: 57.96 (+0.57)
PharmaCyte Biotech to Hold Shareholder Call
GlobeNewswire - Mon Jul 11, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chief Executive Officer, Kenneth L. Waggoner, will conduct a shareholder conference call at 4:30 p.m. EDT on Thursday, July 28, 2016. PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media. PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016. PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research." OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.17 (-0.07)
PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb. PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016. PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology. PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.
PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor. JNJ: 124.24 (+0.38)
PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance. 
